Janux Therapeutics (NASDAQ:JANX) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Analysts have recently evaluated Janux Therapeutics and provided 12-month price targets. The average target is $74.0, accompanied by a high estimate of $100.00 and a low estimate of $42.00. A 3.65% drop is evident in the current av…